about
Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticlesDistribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis.Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysisTreatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data.Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world settingCoronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication.Variation in Care for Patients with Irritable Bowel Syndrome in the United States.Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practiceTreatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine.Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approachDelay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized β2-Agonists.Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers.The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis.Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus.Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.The impact of moderate-to-severe Crohn's Disease on employees' salary growth.Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study.Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis.Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
P50
Q28743086-457C256D-81BC-40E0-A820-44A6E2D1D41AQ30833078-DDDF2C1F-2EF3-485C-B6F8-4BFF767CF70DQ31142213-0795CDED-D44B-4715-BE85-45504913684BQ33721983-93FAD8A4-78E0-41B4-AEFC-252FE99880B2Q33814867-730BB7EF-F35F-4370-873D-E862F001BF7EQ33815059-9D5307A8-2B41-45CC-A516-63285456FA50Q34127931-0ABE1B9C-F212-43DA-837B-E5DE5FEF5EFEQ34618452-F89E65EA-D90F-4698-ADB5-FEC9F7DD45CEQ35884102-26729E6F-0A9B-49A1-9A0E-D2205FD640CFQ35999802-538E36F3-58A9-40B1-9001-19B17DCA3DE1Q36023879-729BB366-726B-44EE-A434-DD54A18F345BQ36754437-2D551D2C-51D8-4FEC-8964-09ECA0502647Q36757388-8BC1197C-8775-426E-9204-5A294D842CD7Q36795368-D6D47F91-E168-4477-8132-944EEE5FA25DQ36908374-016742AC-CC20-4039-91A8-146F1F0BC47DQ37381763-C73418DC-9F54-4171-AFB8-A5AA73034538Q37675253-E79B7221-4236-4277-9DC9-0A164F7603C6Q37808215-B7200CED-2805-43C4-9DAD-F1D5A8B1074CQ37890393-DC8819F8-67C4-4D0E-B056-359DC388EC3DQ38010218-3F651455-BC27-48F2-A557-10A15ECCF68BQ38057808-B54F0A41-7372-4822-905F-5B7B89D788B5Q38091730-4D5075D3-1A03-447A-A5D0-9AE54799A4A4Q38102007-D135FE6A-A2C0-4922-AE8C-5A534C33AC85Q38104424-1FA03F03-BB91-4566-B83F-7546C085987BQ38112200-9DA7054B-2AF0-4EED-B0D1-96E824F74495Q38128400-CE0054D5-609A-4CB2-8FCF-1EE75B8BCF27Q38134145-C2D96E41-6901-403B-BEB0-FB42A881128AQ38159715-3C0C399C-1A43-4755-BFD5-BF1F6737608BQ38176122-0DFEB9CB-4D3B-4768-B5CA-150459689BF7Q38419603-15587587-8C4D-45EF-BE8E-C20C853F9BDCQ38531033-FD33C681-C952-4B89-99C2-58EE95858706Q38552727-2CDE3797-4848-49B3-99A8-E60687BA08EEQ38681227-C7084637-CD33-4603-880B-EC910811EAB6Q38730915-C49F01D1-775F-4B18-902B-BF75F535B3D3Q38746336-4186EA4C-78B7-4881-B2D7-F686BC115081Q38759207-6993BACF-01CF-4562-A8C0-DDC8C69A01DBQ38794931-E582028B-B65F-49DC-B387-8C3FA0AFB486Q38923269-FAD0F932-A730-46E0-A2BE-745D71336BEEQ38948507-B5BBE23B-5812-4DFB-9444-757A704FBEA7Q38997561-197D6D3D-0C4C-4ADE-BBFF-6B6FE89FC37C
P50
name
Annie Guérin
@ast
Annie Guérin
@en
Annie Guérin
@nl
type
label
Annie Guérin
@ast
Annie Guérin
@en
Annie Guérin
@nl
prefLabel
Annie Guérin
@ast
Annie Guérin
@en
Annie Guérin
@nl